Phase II Study of the Effect of Acute Aromatase Inhibition on Breast MRI Postmenopausal Women
Phase 2
40 Years
80 Years
40 Years
80 Years
Open (Enrolling)
Female
Postmenopause
Female
Postmenopause
Trial Information
Phase II Study of the Effect of Acute Aromatase Inhibition on Breast MRI Postmenopausal Women
Inclusion Criteria:
- Women are eligible to participate if they RE 40 years or older and have been
menopausal (had no menstrual bleeding during the past 12 months)
Exclusion Criteria:
- History of bilateral mastectomy, osteoporosis or renal impairment.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
Breast parenchymal background enhancement
Outcome Description:
Objective image analysis of background enhancement of benign breast parenchyma Subjective evaluation of diagnostic confidence by radiologists
Outcome Time Frame:
Three days
Safety Issue:
No
Authority:
Canada: Health Canada
Study ID:
CFWH-AI1
NCT ID:
NCT01129622
Start Date:
October 2008
Completion Date:
September 2010
Related Keywords:
- Postmenopause
- letrozole
- breast MRI
- Postmenopausal women
Name | Location |
|---|
